Drug intelligence / Profile preview

DDS002

Development stage: Preclinical
Lead developer: Renhaim
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

DDS002 is a preclinical-stage mRNA delivery system being developed by Renhaim. It utilizes a lipoplex-based platform to facilitate the delivery of mRNA therapeutics. As of 2024, the program is in the lead optimization stage within Renhaim's pipeline, which focuses on developing proprietary delivery systems for mRNA-based drugs. The system is designed to encapsulate mRNA molecules to protect them from degradation and enhance their uptake into target cells.

Beyond the preview

Go deeper on DDS002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DDS002.

Explore the full profile